AKR2E4 Inhibitor Discovery Platform for Next-Generation Insect Growth Regulators

Overview

This project focuses on developing novel insect growth regulators by targeting AKR2E4, an aldo-keto reductase enzyme in insects that converts inactive 3-dehydroecdysone (3DE) into ecdysone, the central hormone controlling molting and metamorphosis. Because blocking this enzyme could disrupt critical developmental stages in pest species, AKR2E4 represents a promising molecular target for next-generation, species-specific insect control. The research team has already expressed, purified, and kinetically characterized recombinant AKR2E4, and is applying both structure-based drug design (SBDD) and ligand-based drug design (LBDD) to identify potent, selective inhibitors. The resulting compounds could serve as environmentally considerate alternatives or complements to conventional insecticides, addressing growing resistance and regulatory pressures in agriculture and public health.

Technical specifications

• Target enzyme: AKR2E4, an insect aldo-keto reductase that reduces 3-dehydroecdysone (3DE) to active ecdysone, a hormone essential for molting and metamorphosis.
• Structure-based drug design (SBDD): Three-dimensional crystal structure of AKR2E4 in complex with the cofactor NADPH solved at 1.3 angstrom resolution, enabling high-resolution analysis of the active site.
• Ligand-based drug design (LBDD): Ongoing substrate screening assays to identify chemical scaffolds with inhibitory activity against AKR2E4.
• Planned validation: Co-crystallization of AKR2E4 with 3DE to map the substrate-binding site, complemented by molecular docking simulations to predict binding modes and guide lead optimization.
• Timeline: Approximately one year to complete substrate-binding site characterization and initial inhibitor screening.
• Partner need: Access to docking simulation facilities and computational expertise to accelerate virtual screening and binding-mode prediction.

Technology readiness level

The project is at an early-to-mid stage of preclinical discovery. Recombinant AKR2E4 protein has been successfully produced and biochemically validated, and a high-resolution co-crystal structure with NADPH is already in hand. Substrate profiling and co-crystallization studies with 3DE are currently underway. The team is actively seeking a computational partner to support docking simulations, which will feed into lead identification and subsequent optimization. No lead compound has yet been disclosed, and further work on inhibitor potency, selectivity, and insecticidal efficacy in vivo will be required before candidate advancement.